IP Library › Granted Patent US 9,212,361
Granted Patent B2
US 9,212,361 · App. 14/395,080 · Granted Dec 15, 2015

Methods and pharmaceutical compositions for the treatment of hypertension

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,212,361
App. No.
14/395,080
Granted
Dec 15, 2015
Kind
B2
Abstract

The present invention relates to an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) activity or expression for use in a method for treating or preventing hypertension in a subject in need thereof.

Claims (3)

1. A method for treating hypertension in a subject in need thereof, comprising administering to said subject an inhibitor of Neutrophil Gelatinase-Associated Lipocalin (NGAL) gene expression, wherein the subject is a non obese subject.

2. The method according to claim 1 wherein the inhibitor is a siRNA.

3. The method according to claim 1 , wherein the inhibitor is selected from the Group consisting of siRNA, shRNA, anti-sense oligonucleotides and ribozymes.

Assignments (3)
MERGER Recorded Aug 25, 2023
From: UNIVERSITE PARIS DIDEROT-PARIS 7; UNIVERSITE PARIS DESCARTES
To: UNIVERSITE DE PARIS
Reel/Frame 064702/0827 →
CHANGE OF NAME Recorded Aug 25, 2023
From: UNIVERSITE DE PARIS
To: UNIVERSITÉ PARIS CITÉ
Reel/Frame 064727/0194 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 20, 2015
From: JAISSER, FREDERIC; FARMAN, NICOLETTE; TARJUS, ANTOINE
To: INSERM; UNIVERSITE PARIS DIDEROT (PARIS VII); UNIVERSITE PARIS DESCARTES
Reel/Frame 034996/0277 →